ArticleGenetics and molecular biology2026
Therapeutic potential of Brazilian medicinal plants and their metabolites.
Article in Genetics and molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exploring natural products is essential for identifying new bioactive substances with unique molecular structures and mechanisms of action. Successful experiences in identifying and developing chemotherapeutic agents from plant-derived sources have inspired the search for new strategies and alternative treatments for various diseases. Today, more than half of the anticancer drugs in clinical use are derived, directly or indirectly, from natural products. In this review, we present findings from studies on medicinal plants conducted at the Laboratory of Mutagenesis and Oncogenetics, in collaboration with other research groups from the Program Biota/FAPESP, aimed at evaluating their safety for widespread use. Our research team has conducted extensive studies over approximately 25 years, assessing 65 crude plant extracts from 31 species and 8 isolated phytochemicals. Most of these species belong to the Melastomataceae family, followed by the Malpighiaceae family. Among the phytochemicals, flavonoids, diterpenes, indolinones, and alkaloids are the most common. In this comprehensive review, we examine the biological effects identified and their potential therapeutic applications, particularly in the context of anticancer strategies. Our goal is to highlight the pharmacological potential of compounds derived from these plants, thereby supporting the development of drugs that can be effectively utilized in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.